These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 21817854)

  • 61. A pilot clinical trial of a near-infrared laser vaccine adjuvant: safety, tolerability, and cutaneous immune cell trafficking.
    Gelfand JA; Nazarian RM; Kashiwagi S; Brauns T; Martin B; Kimizuka Y; Korek S; Botvinick E; Elkins K; Thomas L; Locascio J; Parry B; Kelly KM; Poznansky MC
    FASEB J; 2019 Feb; 33(2):3074-3081. PubMed ID: 30192655
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Overcoming or circumventing the stratum corneum barrier for efficient transcutaneous immunization.
    Chen Z; Lv Y; Qi J; Zhu Q; Lu Y; Wu W
    Drug Discov Today; 2018 Jan; 23(1):181-186. PubMed ID: 28988995
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Transcutaneous vaccines--current and emerging strategies.
    Hirobe S; Okada N; Nakagawa S
    Expert Opin Drug Deliv; 2013 Apr; 10(4):485-98. PubMed ID: 23316778
    [TBL] [Abstract][Full Text] [Related]  

  • 64. 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin.
    Vogt A; Combadiere B; Hadam S; Stieler KM; Lademann J; Schaefer H; Autran B; Sterry W; Blume-Peytavi U
    J Invest Dermatol; 2006 Jun; 126(6):1316-22. PubMed ID: 16614727
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hair follicle targeting, penetration enhancement and Langerhans cell activation make cyanoacrylate skin surface stripping a promising delivery technique for transcutaneous immunization with large molecules and particle-based vaccines.
    Vogt A; Hadam S; Deckert I; Schmidt J; Stroux A; Afraz Z; Rancan F; Lademann J; Combadiere B; Blume-Peytavi U
    Exp Dermatol; 2015 Jan; 24(1):73-5. PubMed ID: 25382068
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dynamic visualization of dendritic cell-antigen interactions in the skin following transcutaneous immunization.
    Rattanapak T; Birchall JC; Young K; Kubo A; Fujimori S; Ishii M; Hook S
    PLoS One; 2014; 9(2):e89503. PubMed ID: 24586830
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Echographic measurement of skin thickness in sites suitable for intradermal vaccine injection in infants and children.
    Ploin D; Schwarzenbach F; Dubray C; Nicolas JF; Goujon C; Trong MD; Laurent PE
    Vaccine; 2011 Oct; 29(46):8438-42. PubMed ID: 21821081
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [From basic principles to clinical applications on transcutaneous vaccine].
    Okada N
    Yakugaku Zasshi; 2013; 133(12):1363-72. PubMed ID: 24292185
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Opportunities and challenges of the pulmonary route for vaccination.
    Blank F; Stumbles P; von Garnier C
    Expert Opin Drug Deliv; 2011 May; 8(5):547-63. PubMed ID: 21438741
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Laser microporation of the skin: prospects for painless application of protective and therapeutic vaccines.
    Scheiblhofer S; Thalhamer J; Weiss R
    Expert Opin Drug Deliv; 2013 Jun; 10(6):761-73. PubMed ID: 23425032
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Nanoparticles for transcutaneous vaccination.
    Hansen S; Lehr CM
    Microb Biotechnol; 2012 Mar; 5(2):156-67. PubMed ID: 21854553
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Transcutaneous immunization with Intercell's vaccine delivery system.
    Seid RC; Look JL; Ruiz C; Frolov V; Flyer D; Schafer J; Ellingsworth L
    Vaccine; 2012 Jun; 30(29):4349-54. PubMed ID: 22682290
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A grading system for local skin reactions developed for clinical trials of an intradermal and transcutaneous ETEC vaccine.
    Gutiérrez RL; Porter CK; Jarell A; Alcala A; Riddle MS; Turiansky GW
    Vaccine; 2020 May; 38(21):3773-3779. PubMed ID: 32253098
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Enhancing tumor specific immune responses by transcutaneous vaccination.
    Saliba H; Heurtault B; Bouharoun-Tayoun H; Flacher V; Frisch B; Fournel S; Chamat S
    Expert Rev Vaccines; 2017 Nov; 16(11):1079-1094. PubMed ID: 28937293
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases.
    Korkmaz E; Balmert SC; Carey CD; Erdos G; Falo LD
    Expert Opin Drug Deliv; 2021 Feb; 18(2):151-167. PubMed ID: 32924651
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Langerhans cells: critical regulators of skin immunity?
    Clausen BE; Kel JM
    Immunol Cell Biol; 2010; 88(4):351-60. PubMed ID: 20351747
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Microneedle-mediated vaccine delivery: harnessing cutaneous immunobiology to improve efficacy.
    Al-Zahrani S; Zaric M; McCrudden C; Scott C; Kissenpfennig A; Donnelly RF
    Expert Opin Drug Deliv; 2012 May; 9(5):541-50. PubMed ID: 22475249
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Transcutaneous immunization of domestic animals: opportunities and challenges.
    Hammond SA; Tsonis C; Sellins K; Rushlow K; Scharton-Kersten T; Colditz I; Glenn GM
    Adv Drug Deliv Rev; 2000 Sep; 43(1):45-55. PubMed ID: 10967220
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Development of an Immune Regulation Technology Targeting the Skin and Promotion of the Practical Applications of Transcutaneous Vaccination/Immunotherapy].
    Okada N
    Yakugaku Zasshi; 2019; 139(9):1129-1137. PubMed ID: 31474627
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Topically applied virus-like particles containing HIV-1 Pr55
    Rancan F; Afraz Z; Hadam S; Weiß L; Perrin H; Kliche A; Schrade P; Bachmann S; Schäfer-Korting M; Blume-Peytavi U; Wagner R; Combadière B; Vogt A
    J Control Release; 2017 Dec; 268():296-304. PubMed ID: 29080666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.